Netherlands· NL-20ee61c65f5e
Ranolazine ELC 375 mg, tabletten met verlengde afgifte
A ranolazine product containing ranolazine, registered in Netherlands by ELC Group s.r.o.. The same ATC class is registered in 16 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Ranolazine is registered in 16 of 19 countries.
Countries holding a registration under ATC C01EB18 (ranolazine), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Ranolazine · ATC C01EB18
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ranolazine costs, country by country.
Normalised to the WHO defined daily dose (1.5 g), the median price runs from $0.49 in United States to $5.07 in Switzerland — a ×10 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Ranolazine · price per daily dose (1.5 g)
USD · FX 28 Sept 2026
- CH Switzerland$5.07
- ES Spain$1.58
- IT Italy$0.87
- US United States$0.49 (acquisition cost)
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- RANOLAZINE
- Manufacturer
- ELC Group s.r.o.
- Country
- Netherlands (NL)
- ATC code
- C01EB18
- ATC class
- Ranolazine
- Defined daily dose
- 1.5 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id127790
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
335 interactions on record for ranolazine.
Graded by severity as the source publishes them — 78 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ranolazine · interactions on record
335 records
- 78 severe
- 205 moderate
- 29 minor
- 23 info
Most severe, free to view
- ClotrimazoleA01AB18severe
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ranolazine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainLABIGAT 375 MG COMPRIMIDOS DE LIBERACION PROLONGADA EFGPharmathen S.A.
- United KingdomAnzipro 375mg modified-release tabletsRidge Pharma Ltd
- CzechiaRANEXAMenarini International Operations Luxembourg S.A., Luxembourg
- ItalyRANEXAMENARINI INTERNAT. O.L.S.A
- IrelandRanexa 375 mg prolonged-release tabletsMenarini International Operations Luxembourg S.A.
- PolandRalikFarmak International Sp. z o.o.
- NorwayRanexaMenarini
- SwedenRanexa 375 mg DepottablettMenarini International Operations Luxembourg SA
Authorised across Europe · EMA
The same active substance is authorised in 23 EEA countries. Names it is sold under:
- Austria · Rande, Ranogelan
- Bulgaria · Равена
- Cyprus · Ranolazine Accord, Ranolazine Remedica
- Czechia · Ranolazine Umedica
- Germany · Halibrell, Labigat
- Denmark · Labigat
- Estonia · Halibrell, Ralik
- Spain · Labigat, Ranolazina Alter
- France · Ranolazine Micro Labs
- United Kingdom (Northern Ireland) · Ranolazine, Ranolazine Accord
- Greece · Labigat, Lakosun
- Croatia · Halibrell, Lasokun
- Ireland · Ranolazine Accord, Ranolazine Clonmel
- Iceland · Ranexa
- Italy · Labigat, Ranolazina Accord
- Liechtenstein · Ranexa
- Lithuania · Halibrell, Lasokun
- Latvia · Halibrell, Lasokun
- Norway · Ranexa
- Poland · Ralik, Ranolazine Aurovitas
- Portugal · Ranolazina Adamed, Ranolazina Bluepharma
- Romania · Ranolazina Atb
- Slovenia · Halibrell, Ranolazin Stada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ce9ded39-d172-4512-90cb-98a4318e4101 GET /v1/drugs/ce9ded39-d172-4512-90cb-98a4318e4101?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet met verlengde afgifte",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h127790_smpc.pdf",
"strength": null,
"atc_label": "Ranolazine",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg127790",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"COPOLYMEER VAN ETHYLACRYLAAT-METHACRYLZUUR (1:1)",
"HYPROLOSE (E 463)",
"HYPROMELLOSE (E 464)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"MACROGOL 8000",
"MAGNESIUMSTEARAAT (E 470b)",
"NATRIUMHYDROXIDE (E 524)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"RANOLAZINE"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h127790.pdf",
"authorised_at": "2022/07/21",
"procedure_number": "NL/H/5342/001",
"dispensing_status": "Uitsluitend recept",
"registration_number": "127790",
"additional_monitoring": "N"
}See everything about ranolazine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.